Showing 4801-4810 of 5554 results for "".
- Rosacea Awareness Month Brings Focus to Common Skin Diseasehttps://practicaldermatology.com/news/rosacea-awareness-month-brings-focus-to-common-skin-disease/2460342/It’s Rosacea Awareness Month, and the National Rosacea Society (NRS) continues to educate the public on this potentially serious condition estimated to affect more than 16 million Americans. “Although the occurrence of rosacea has been well documented over the centuries, vir
- Dermavant Completes Patient Enrollment for Two Phase 3 Clinical Trials of Tapinarof for Psoriasishttps://practicaldermatology.com/news/dermavant-completes-patient-enrollment-for-two-phase-3-clinical-trials-of-tapinarof-for-psoriasis/2460339/Dermavant Sciences completed patient enrollment in PSOARING 1 and PSOARING 2 clinical trials of tapinarof, a potential first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA), in adult patients diagnosed with plaque psoriasis. Dermavant expects t
- Dupixent Significantly Improves Severe AD in Childrenhttps://practicaldermatology.com/news/dupixent-significantly-improves-severe-ad-in-children/2460338/Dupixent showed significant improvement in severe atopic dermatitis (AD) for children aged 6 to 11 Years, according to a Phase 3 study. In the trial, Dupixent combined with standard-of-care topical corticosteroids (TCS) significantly improved disease signs, symptoms and health-related q
- Industry Responds to COVID-19: Allergan Foundation; AG Hair; Revancehttps://practicaldermatology.com/news/industry-responds-to-covid-19-allergan-foundation-ag-hair-revance/2460326/Allergan. Of the approximately $13 million in charitable grants the Allergan Foundation has awarded in 2020, a total of $2 million will be dedicated to more than 70 organizations responding to the local impact of the COVID-19 pandemic. Other grant recipients i
- Telehealth Webinar from Cosmetic Surgery Forum Explores Best Practiceshttps://practicaldermatology.com/news/telehealth-webinar-available-from-cosmetic-surgery-forum/2460325/As dermatologists deal with the evolving COVID-19 crisis, they are increasingly searching for guidance on the proper use of telemedicine. Joel Schlessinger, MD, Founder of Cosmetic Surgery Forum, brought together George Hruza, MD, past president of the AAD, and Antoanella Calame, MD, founder of t
- Positive Phase 3 Results Reported for Medimetriks and Otsuka's AD Drughttps://practicaldermatology.com/news/positive-phase-3-results-reported-for-medimetriks-and-otsukas-ad-drug-1/2460322/Medimetriks Pharmaceuticals, Inc. and Otsuka Pharmaceuticals Co. Ltd.’s MM36 (difamilast) performed well in two Phase 3 Japanese clinical trials in adult and pediatric atopic dermatitis (AD) patients. Difamilast is a novel topical, non-steroidal phosphodiesterase IV (PDE4) inhibit
- Destiny Pharma and MedPharm Complete Initial Phase of Development Projecthttps://practicaldermatology.com/news/destiny-pharma-and-medpharm-complete-initial-phase-of-development-project/2460318/Destiny Pharma and MedPharm have completed the initial phase of their project to develop new topical formulations of Destiny’s novel XF‐platform drugs. Further to forming the collaboration with MedPharm last year, the project has identified a range of new, stable XF formulations w
- Zylö Therapeutics a Finalist in the Buzz of BIO Contesthttps://practicaldermatology.com/news/zylo-therapeutics-a-finalist-in-the-buzz-of-bio-contest/2460311/Voting ends tonight for the Buzz of BIO contest, sponsored by BIO, the world's largest trade association representing biotechnology companies. Zylö Therapeutics, which has dermatology as one of its focus areas, is a finalist in the “Pipelines of Promise”
- FDA Grants Breakthrough Status for Baricitinib in AAhttps://practicaldermatology.com/news/fda-grants-breakthrough-status-for-baricitinib-in-alopecia-1/2460308/The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Eli Lilly and Company and Incyte Corporation’s baricitinib for the treatment of alopecia areata (AA). Baricitinib is currently approved for the treatment of adults with moderately to severe
- First Patient Enrolled in Avita Medical’s Pivotal Study Evaluating Recell System for Soft Tissue Reconstructionhttps://practicaldermatology.com/news/first-patient-enrolled-in-avita-medicals-pivotal-study-evaluating-recell-system-for-soft-tissue-reconstruction/2460294/Avita Medical Limited enrolled the first patient in a study evaluating the Recell System for Soft Tissue Reconstruction at the Arizona Burn Center at Valleywise Medical Health Center in Phoenix, AZ. The prospective multi-center trial of at least 65 patients will compare the clinical per